ProKidney reports Q3 net loss $35.8M, cash $271.7M; Phase 3 PROACT 1 enrollment >50%, topline Q2 2027

PROKIDNEY CORP.

Q3 net loss before noncontrolling interest $35.8M vs $41.1M YoY; R&D expenses $26.8M.
Cash and equivalents $271.7M, expected to fund operations into mid-2027.
Phase 3 PROACT 1 accelerated approval analysis: >50% of ~360 patients enrolled, topline results Q2 2027.
FDA confirmed eGFR slope as surrogate endpoint for BLA under accelerated approval; RMAT designation continues.
Phase 2 REGEN-007 data at ASN: 78% improvement in eGFR decline (p<0.001); well tolerated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.